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SUMMARY. The goal of hepatitis B treatment is to prevent the
development of cirrhosis, liver failure, and hepatocellular
carcinoma. Ideally, clinical studies should demonstrate that
hepatitis B therapies can prevent liver-related complications;
however, these clinical endpoints evolve over years or
decades. Therefore, clinical trials have relied on intermediate
endpoints to evaluate the efficacy of treatment and to deter-
mine when treatment can be stopped. Intermediate endpoints
that have been used include biochemical, histological, viro-
logical, and serological endpoints. This review will discuss the
validity of these intermediate endpoints as surrogates of clin-
ical endpoints, and the rates at which these intermediate
endpoints can be achieved with currently available therapies.
Keywords: alanine aminotransferase, HBeAg seroconversion,
HBsAg loss, HBV DNA, liver histology.
INTRODUCTION
The ultimate goal of chronic infectious disease treatment is
the eradication of the infectious agent; however, eradication
of hepatitis B virus (HBV) is not a realistic goal of hepatitis B
treatment. Currently available nucleos(t)ide analogues
(NUCs) act mainly as inhibitors of the reverse transcription
of the pregenomic RNA to HBV DNA and have no direct
effect on the covalently closed circular DNA (cccDNA) – the
template for the transcription of the pregenomic RNA as well
as for the translation of viral proteins. This accounts for the
high rate of viral relapse when treatment is stopped. Indeed,
even in persons who have serological recovery from an acute
HBV infection, HBV DNA remains detectable in the liver and
reactivation of HBV replication can occur when those per-
sons receive immunosuppressive therapy [1]. Recent studies
suggest that clearance of cccDNA relies on the turnover of
infected hepatocytes [2,3]. This may explain the higher rate
of sustained off-treatment response to interferon (IFN)
therapy even though IFN has weaker antiviral activity
compared to NUCs.
CLINICAL ENDPOINTS VS INTERMEDIATE
(SURROGATE) ENDPOINTS
The goal of hepatitis B treatment is to prevent the develop-
ment of cirrhosis, liver failure, and hepatocellular carcinoma
(HCC). These clinical endpoints take decades to evolve.
Clinical trials designed to demonstrate a benefit on clinical
outcomes would need to enrol hundreds or thousands of
patients at risk for these events followed for many years or
decades; therefore, clinical trials of hepatitis B treatment
have relied on intermediate endpoints that reflect viral rep-
lication and liver disease activity as surrogates for clinical
benefit. The intermediate endpoints used include virological
endpoint (suppression of serum HBV DNA to undetectable by
a sensitive PCR assay), serological endpoint [loss of hepatitis
B e antigen (HBeAg) with or without seroconversion to
hepatitis B e antibody (anti-HBe)], biochemical endpoint
[normalization of alanine aminotransferase (ALT)], as well
as histological endpoint (decrease in necrosis and inflam-
mation score by ‡2 points with no worsening of fibrosis). The
criteria for surrogate endpoints are summarized in Table 1.
An expert review panel questioned the validity of these
intermediate endpoints as surrogates for clinical outcomes
[4]. The panel cited the lack of data from randomized con-
trolled trials (RCTs) demonstrating that achievement of the
intermediate endpoints translates into decreased clinical
outcomes. While data from RCTs are more vigorous, evi-
dence supporting the validity of intermediate endpoints as
surrogates for clinical outcomes can be deduced from natu-
ral history studies linking cirrhosis, liver failure, HCC, or
liver-related mortality with elevated ALT, high HBV DNA, or
persistent presence of HBeAg. In addition, long-term follow-
up studies of patients who received antiviral treatment can
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be used to show that patients who have intermediate
responses have improved clinical outcomes. Therefore, reg-
ulatory authorities have relied on intermediate endpoints to
evaluate the benefits of new HBV treatment, and professional
guidelines have recommended the use of intermediate end-
points to determine treatment response and when treatment
can be stopped [5–7]. This review will discuss evidence
supporting the validity of the intermediate endpoints as
surrogates for clinical endpoints in HBV treatment and
the rate at which these endpoints can be achieved with
currently available treatments.
BIOCHEMICAL ENDPOINT
Serum ALT is a cheap and readily available marker of liver
inflammation. Phase III clinical trials of HBV treatment have
included ALT normalization as an indicator of efficacy. ALT
normalization has been observed in 34–51% of patients at
the end of a 48–52 week course of pegylated interferon (peg-
IFN) with or without lamivudine and in 41–78% of patients
after 1 year of NUC therapy [8–17] (Table 2). Studies of
long-term NUC therapy found that ALT normalization
increased to 66–80% after 5 years of treatment [18–21].
These data indicate that antiviral treatment can result in
ALT normalization in most patients, but follow-up studies
showed that ALT remained normal in only 32–60% of
patients within 6 months of discontinuing a 1-year course of
peg-IFN [8,9,21] and in 32–49% of patients 6–12 months
after completing a 1-year course of NUC therapy [22,23].
Furthermore, ALT flares have been reported in 1–29% of
patients 4–6 months after completing a 1-year course of
NUC therapy, and in some instances, these flares have
resulted in liver failure [11,14,15,24]. Thus, ALT normali-
zation, particularly if short-lived, is not a reliable surrogate
of clinical outcome.
Recent data from studies of patients not receiving antiviral
therapy found that persons with normal ALT can have
abnormal liver histology, liver complications and liver-re-
lated deaths. These studies showed that up to 37% of persons
with chronic HBV infection and normal ALT had significant
inflammation and/or fibrosis on liver biopsy [25,26]. One
study followed 142 055 persons, aged 35–59 years for a
mean of 8 years after a health examination. Compared to
those with baseline ALT <20 IU/L, persons with ALT at
enrolment of 20–29 IU/L and 30–39 IU/L had a 2.5-fold
and eightfold risk of deaths from liver disease, respectively,
for men and a 3.3-fold and 18.2-fold risk of deaths from liver
disease, respectively, for women [27]. Another study of 3233
patients with chronic hepatitis B found that patients with
ALT 1–2 times the upper limit of normal (·ULN) and those
with ALT 0.5–1 · ULN had higher cumulative risks of liver
complications compared to patients with ALT < 0.5 · ULN
[28].
Thus, data from patients not on treatment indicate that
lower ALT is associated with improved clinical outcome, but
decreasing ALT to the normal range defined by most clinical
diagnostic laboratories may not be sufficient to prevent liver
complications and liver-related deaths. These findings have
led to a re-examination of the true ULN for ALT. A study of
Italian blood donors suggested that the ULN for ALT should
be 30 IU/L for men and 19 IU/L for women [29], while a
recent study of 1105 potential liver donors in Korea all of
whom had a biopsy-proven normal liver found that the ULN
for ALT should be 35 IU/L for men and 26 IU/L for women
[30]. Given the uncertainty regarding the upper limit for
ALT in persons with normal livers, the legitimacy of ALT
normalization as an intermediate endpoint is questionable.
HISTOLOGICAL ENDPOINT
Improvement in liver histology was used as the primary
endpoint in many phase III clinical trials of HBV treatment
because traditionally liver histology is considered to be the
most accurate assessment of liver disease. In most studies,
histological improvement was defined as a ‡2-point decrease
in the histology activity index (HAI) with no worsening of
fibrosis between the pretreatment and end-of-treatment
biopsies. Using this definition, histological improvement has
been reported to occur in 38–48% of patients after a 1-year
course of peg-IFN treatment [8,9] and in 49–74% of patients
Table 1 Definition of clinical endpoints and surrogate endpoints
Term Definition
Clinical endpoint A characteristic or variable that reflects how a patient feels, functions, or survives
Surrogate endpoint A biomarker that is intended to substitute for a clinical endpoint that should predict clinical
benefit or harm or lack of both
Criteria for surrogate
endpoint
Should be easier to assess and occur more often than the corresponding clinical endpoint
Should be in the causal pathway to the outcome
The effect of an intervention on the surrogate endpoint must explain the effect on subsequent
clinical outcomes
References: [60], [61].
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after a 1-year course of NUC treatment [10–17] compared to
24–33% of patients who received placebo or no treatment
[10–13] (Table 2). These data demonstrated that antiviral
therapy can result in improvement in liver histology, but
it should be noted that fibrosis scores remained largely
unchanged with these short courses of treatment, and in
studies of NUCs, follow-up biopsies were performed while the
patients were still receiving treatment.
Studies of patients receiving longer courses of NUC
showed that necrosis and inflammation continued to
decrease and fibrosis regressed in patients with maintained
viral suppression. One study compared liver histology pre-
treatment, after 1 year of lamivudine and after 3 years of
lamivudine. Compared to the year-1 biopsy, further reduc-
tion in necrosis and inflammation on the year-3 biopsy was
observed in 19% of patients. Of note, eight of 11 patients had
regression of cirrhosis, while only one of 52 had progression
to cirrhosis after 3 years of lamivudine treatment [31]. In
another study of 45 HBeAg-negative patients treated with
adefovir, the proportion of patients with regression of fibrosis
as measured by a ‡1 point decrease in Ishak fibrosis score
increased from 35% at 1 year to 71% after 5 years of
treatment and seven of the 12 patients (58%) with bridging
fibrosis or cirrhosis on the pretreatment biopsy had decrease
in Ishak fibrosis score by ‡2 points [19]. In a third study of
63 patients treated with entecavir for a median of 6 years
(range 3–7), a ‡1 point decrease in Ishak fibrosis score was
observed in 88% of the patients and cirrhosis was no longer
demonstrated in three of four patients who had cirrhosis
before treatment [32]. Thus, antiviral therapy has been
shown not only to prevent progression of liver disease but
also to reverse fibrosis.
Although liver histology is the most direct assessment of
liver disease, histology is not a practical endpoint of HBV
treatment in clinical practice. Assessment of histological
endpoint will require at least two biopsies. Liver biopsy is an
invasive and expensive procedure that may be associated
with a small risk of serious complications. Furthermore, liver
histology is not always accurate because of sampling error,
particularly when the biopsy samples are small [33].
Table 2 Rates of intermediate endpoints during or after antiviral treatment in (a) HBeAg-positive patients (b) HBeAg-negative
patients
Peg-IFN Peg-IFN + LAM LAM ADV ETV LdT TDF
(a) HBeAg-positive patients
Responses at year 1
ALT normalization 34–39 (32–41)* 46–51 (35–39)* 41–75 (28)* 48 68 77 68
Histologic improvement 22 (38)* 33 (41)* 49–56 (34)* 53 72 65 74
Undetectable HBV DNA 10–25 (7–14)* 33–69 (9–14)* 36–44 (5)* 21 67 60 76
HBeAg seroconversion 29–30 (29–32)* 24–25 (27–29)* 16–21 (12.4–19)* 12 21 (15.3)* 22 21
HBsAg loss 5 (3–5)* 7 (3–7)* £ 1 (0)* 0 2 0 3.2
Responses at year 3–5
ALT normalization 28 33 69 66 80 86 N/A
Undetectable HBV DNA 13 26 N/A 39 82–94 75–79 95
HBeAg seroconversion 35 25 47 37–48 40 39–42 26
HBsAg loss 8 15 N/A 2 6 2 8
(b) HBeAg-negative patients
Responses at year 1
ALT normalization 38 (59)* 49 (60)* 62–78 (39–44)* 72 (32)* 78 (49)* 74 76
Histologic improvement N/A (48)* N/A (38)* 61–66 (40)* 64 70 67 72
Undetectable HBV DNA 63 (19)* 87 (20)* 60–73 (5–7)* 51 (8)* 90 (3)* 88 93
HBsAg loss N/A (4)* N/A (3)* £ 1 (0)* 0 (0)* <1 <1 0
Responses at year 3–5
ALT normalization 31 31 N/A 69 N/A 91 N/A
Undetectable HBV DNA 18 13 N/A 67 N/A 84 99.1
HBsAg loss 8 8 N/A 5 N/A N/A N/A
Data expressed as percent.
References: [8–18], [20–23], [34,35], [38,39], [51], [62], [63], [64].
Peg-IFN, pegylated interferon; LAM, lamivudine; ADV, adefovir; ETV, entecavir; LdT, telbivudine; TDF, tenofovir, ALT, alanine
aminotransferase; N/A, not available; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus.
*Data in bracket show responses 6 months after stopping treatment.
Off-treatment response.
 2010 Blackwell Publishing Ltd
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VIROLOGICAL ENDPOINT
Suppression of HBV replication with undetectable serum
HBV DNA when tested by a sensitive PCR assay has been
used as an endpoint in all clinical trials of HBV treatment.
Phase III clinical trials of peg-IFN showed that virological
response could be achieved in 10–69% of HBeAg-positive
and in 63–87% of HBeAg-negative patients at the end of a
1-year course of peg-IFN alone or in combination with
lamivudine [8,9] (Table 2). A higher rate of virological
response was observed in patients who received combination
therapy of peg-IFN and lamivudine [8,9,21]. However, ser-
um HBV DNA remained undetectable in only 7–14% of
HBeAg-positive patients and in 19–20% of HBeAg-negative
patients 6 months after stopping treatment, and the
response rates were similar in patients who received peg-IFN
alone or peg-IFN plus lamivudine (Table 2). Long-term
follow-up studies showed that only 19% of HBeAg-positive
patients and 15.6% of HBeAg-negative patients had sus-
tained viral suppression 3–5 years after completing a 1-year
course of peg-IFN treatment [34,35].
NUC therapy has more potent antiviral activity than IFN.
Phase III clinical trials of NUCs showed that virological re-
sponse could be achieved in 21–76% of HBeAg-positive and
in 51–93% of HBeAg-negative patients at the end of a 1-year
course of treatment [10–17] (Table 2). Of the five approved
HBV NUCs, entecavir, telbivudine, and tenofovir were
associated with higher rates of virological response, followed
by lamivudine and then adefovir. Withdrawal of therapy
after a 1-year course is associated with rapid viral relapse,
and serum HBV DNA remained undetectable in only 5%
of HBeAg-positive patients and in 3–8% of HBeAg-
negative patients 6–12 months after stopping treatment
[8,9,22,23,36]. By contrast, follow-up of patients who
received long-term NUCs that have modest-high genetic
barrier to resistance showed that an increasing proportion of
patients achieved virological response. In a study of 125
HBeAg-negative patients who had received adefovir for
4–5 years, 72% had undetectable serum HBV DNA com-
pared to 67% after 1 year of treatment [13,19]. In another
study of 354 HBeAg-positive patients receiving entecavir,
virological response increased from 67% at the end of
1 -year to 94% at the end of 5- year treatment [20].
Virological breakthrough was observed in only 28 patients
(approximately 2%/year) through the 5-year course of
treatment [37]. In a third study of 176 HBeAg-positive and
250 HBeAg-negative patients receiving tenofovir, virological
response increased from 76% at the end of 1- year to 95% at
the end of 3- year treatment among the HBeAg-positive
patients and from 93% to 99% among the HBeAg-negative
patients. Virological breakthrough was observed in only 14
patients through the 3-year course of treatment [17,38,39].
These studies showed that viral suppression is maintained
in the vast majority of patients receiving long-term NUCs
that have high genetic barrier to resistance.
The clinical benefit of treatment-related viral suppression
was demonstrated in a prospective, double-blind RCT of
lamivudine in 651 patients with advanced fibrosis or cir-
rhosis [40]. After a median of 32 months, a statistically
significant difference in the incidence of the primary end-
point defined as an increase in Child-Turcotte-Pugh (CTP)
score of ‡2 points, variceal haemorrhage, spontaneous
bacterial peritonitis, or HCC was observed between the
treated patients and controls [7.8% vs 17.7%, hazard ratio
(HR) 0.45, 95% CI 0.28–0.73, P = 0.001]. This trial also
demonstrated a statistically significant decrease in the inci-
dence of HCC among the treated patients, 3.9% vs 7.4% in
the controls (P = 0.047). In this study, a clinical endpoint
was observed in 11% of treated patients with and in 5% of
patients without lamivudine resistance mutations compared
to 18% of those on placebo. The benefit of treatment-related
viral suppression was also shown in a retrospective study of
656 patients (46% had cirrhosis) who had received lami-
vudine for a median of 22 (range 1–66) months [41].
Among the patients with cirrhosis, HCC and death occurred
less frequently in those who had maintained viral suppres-
sion compared to those with virological breakthrough.
Virological response had also been shown to be associated
with histologic improvement. A review of 26 prospective
clinical studies of antiviral therapy involving 3428 patients
who had pretreatment and post-treatment liver biopsies
found that treatment-associated decrease in necrosis and
inflammation was directly proportional to the reduction in
serum HBV DNA levels [42].
Several large cohort studies of patients not receiving
antiviral treatment have demonstrated a strong association
between high serum HBV DNA level and an increased risk of
developing cirrhosis, HCC, and liver-related death. In one
study of 3653 hepatitis B surface antigen (HBsAg)-positive
persons followed for 11.4 years in whom HBV DNA levels at
baseline and the last follow-up visit were available, the
adjusted HR for HCC was 4.3–5.3 (95% CI 2.9–9.7) among
those with both HBV DNA values more than 100 000 cop-
ies/mL and 1.9 (95% CI 0.8–4.4) for those with HBV DNA
more than 100 000 copies/mL at enrolment and <10 000
copies/mL at the last follow-up visit, when compared to
those who had HBV DNA <10 000 copies/mL at enrolment.
This study showed that persistently high serum HBV DNA
was associated with an increased risk of HCC development
and decrease in serum HBV DNA during follow-up was
associated with a reduction in risk of HCC [43]. In another
analysis of this cohort, the cumulative incidence of cirrhosis
was reported to be 4.5% and 36.2% for patients with base-
line HBV DNA level <300 copies/mL and ‡1 000 000
copies/mL, respectively [44].
Substantial data support that persistently high serum HBV
DNA is associated with an increased risk of clinical outcome
and suppression of serum HBV DNA as a result of host
immune response or antiviral treatment results in improved
liver histology and decreased risk of clinical outcome.
 2010 Blackwell Publishing Ltd
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Clinical trials showed that approved treatments for hepatitis
B are effective in suppressing HBV replication, but only a
small percent of patients achieved sustained virological
response when treatment is discontinued. Therefore, while
virological endpoint is an important parameter of success of
hepatitis B treatment, it is not a reliable surrogate for clinical
outcome unless viral suppression is sustained after discon-
tinuation of treatment or maintained during continued
treatment. [22].
SEROLOGICAL ENDPOINTS
Hepatitis B e antigen seroconversion
Hepatitis B e antigen seroconversion is an important endpoint
in clinical trials of antiviral therapy in HBeAg-positive
patients. Phase III clinical trials showed that a 1-year course
of peg-IFN resulted in HBeAg seroconversion in 24–30% of
patients at the end of treatment, and addition of lamivudine
did not increase the rate of HBeAg seroconversion (Table 2).
HBeAg seroconversion was durable in most (81%) patients
after peg-IFN was stopped, and incremental HBeAg serocon-
version was observed during post-treatment follow-up [34].
Phase III clinical trials showed that a 1-year course of
NUC resulted in HBeAg seroconversion rates of 16–22%
(Table 2a). The durability of NUC-induced HBeAg serocon-
version has been reported to vary from 62 to 77% when
treatment was stopped after 1 year [45,46]. Factors associ-
ated with durability of HBeAg seroconversion include a
longer duration of consolidation therapy (12 months),
younger age of the patient (<40 years), HBV genotype B (vs
C), and lower HBV DNA level at the time treatment was
stopped [47–50]. Continued treatment with NUC resulted
in increasing rates of HBeAg seroconversion to 26–31%
after 2 years and to 40–50% after 5 years of treatment
[20,35,51].
Studies of patients not receiving antiviral therapy showed
that presence of HBeAg was associated with a higher risk of
development of cirrhosis and HCC. In a prospective study of
2361 HBsAg-positive men followed for 92 359 person-years,
those who were HBeAg positive at enrolment had a relative
risk of HCC sixfold higher than those who were HBeAg
negative [52]. Cohort follow-up studies showed that patients
who underwent spontaneous HBeAg seroconversion had
favourable outcome particularly if the HBeAg seroconver-
sion occurred early in the course of chronic HBV infection
and was durable, and the outcome was improved compared
to patients who remained HBeAg positive. In one study, 88%
of 223 patients who underwent HBeAg seroconversion had
sustained normalization of ALT and 79% had histologic
improvement [53]. In a follow-up report of the same cohort,
66% remained as inactive carriers after a median follow-up
of 25 years [54]. The 25-year probability of survival was
40% for those who remained HBeAg positive, 50% for those
progressing to HBeAg-negative chronic hepatitis or reverting
to HBeAg positive, and 95% for those whose HBeAg sero-
conversion was maintained. In another study, 283 patients
underwent spontaneous HBeAg seroconversion. Of the 269
patients who had no evidence of cirrhosis at the time of
HBeAg seroconversion, 21 developed cirrhosis during a
mean follow-up of 9 years, 14 of 62 patients who progressed
to HBeAg-negative hepatitis, five of nine who had HBeAg
reversion, one of 14 patients who had active hepatitis of
undetermined causes, and one of 184 who had sustained
HBeAg seroconversion [55]. A third study of 483 patients
followed for a mean of 11.7 years found that patients who
underwent HBeAg seroconversion before age 30 had excel-
lent prognosis when compared to those who did so at an
older age. The cumulative incidence of cirrhosis was 3.7%,
12.9%, and 42.9% and for HCC 2.1%, 3.2%, and 7.7% in
patients who underwent HBeAg seroconversion before age
30 years, at age 31–40 years and after age 40 years,
respectively [56].
Follow-up studies of patients who received HBV treatment
also support the use of HBeAg seroconversion as a surrogate
marker for clinical outcome. In a study by Niederau et al.,
103 patients who were treated with IFN alfa and 53
untreated controls were followed for a mean of 50.0 ±
19.8 months. Fifty (49%) of the IFN-treated patients lost
HBeAg compared to 7 (13%) of the untreated controls. Liver-
related complications occurred in 16 (16%) treated patients
all but one of whom failed to lose HBeAg and in 13 (25%)
controls. Survival until liver transplantation or death and
lack of clinical complications was significantly better in
treated patients who cleared HBeAg than in patients who did
not (P = 0.004 for survival and P = 0.018 for absence of
clinical complications). In another study, Lau et al. [57]
followed 103 patients who received IFN treatment for a
mean of 6.2 years. Patients who did not clear HBeAg had
higher rates of liver-related complications and mortality
(HR = 13.7, 95% CI 3.0–63.5) compared to those who lost
HBeAg within 1 year of treatment.
These studies demonstrate that HBeAg seroconversion,
spontaneous or treatment related, is associated with
improvement in liver histology and clinical outcomes
including survival. Therefore, HBeAg seroconversion is a
valid surrogate endpoint for clinical outcome, and treatment
guidelines have recommended that NUC treatment can be
stopped in patients who completed at least 6- month con-
solidation therapy after confirmed HBeAg seroconversion.
Many experts have questioned the validity of HBeAg sero-
conversion as an endpoint of HBV treatment citing that HBV
DNA remains detectable in most patients albeit at lower
levels and reactivation of HBV replication with recrudes-
cence of hepatitis leading to progressive liver disease will
ultimately occur in most patients. However, one study
involving 283 patients followed for a median of 8.6 years
(range, 1–18.4 years) after HBeAg seroconversion found
that only 4.2% had HBeAg reversion and 24% developed
HBeAg-negative hepatitis with detectable HBV DNA, while
 2010 Blackwell Publishing Ltd
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the other 71.8% remained in remission [55]. Given the high
costs of NUCs and the risks of adverse events and antiviral
resistance during long-term therapy, withdrawal of treat-
ment in patients who have completed 12 months of con-
solidation therapy after confirmed HBeAg seroconversion
and who have undetectable serum HBV DNA is a reasonable
approach as long as the patients continue to be monitored. A
recent study of patients who achieved HBeAg seroconversion
during lamivudine treatment showed that durability of
HBeAg seroconversion was 92% after 5 years of post-treat-
ment follow-up among the patients who completed at least
12 months of consolidation therapy [48]. These data indi-
cate that durable HBeAg seroconversion can be accom-
plished with NUC treatment.
Hepatitis B surface antigen loss
Hepatitis B surface antigen is the hallmark of HBV infection.
Clinical trials showed that HBsAg loss can be observed in 5–
7% of patients at the end of a 1-year course of peg-IFN with
or without lamivudine [8,9] and in 0–3.2% of patients at
the end of a 1-year course of NUC therapy [10–17]
(Table 2). Long-term follow-up of patients who received
peg-IFN with or without lamivudine found that the rate of
HBsAg loss increased to 8–15% in HBeAg-positive patients
and 8% in HBeAg-negative patients 3 years after comple-
tion of a 1-year course of peg-IFN [34,35]. However, it
should be noted that the rate of HBsAg loss was not uniform
across HBV genotypes. In a study of HBeAg-positive
patients, HBsAg loss at 3 years was observed in 28%
patients with genotype A but in only 3% of patients with
other HBV genotypes [34]. Another study of 230 HBeAg-
negative patients followed for 3 years after peg-IFN treat-
ment found that HBsAg loss was observed in 9.4% of
patients who had undetectable HBV DNA (<400 copies/mL)
at the end of treatment compared to only 2% of those who
remained viremic at the end of treatment [35]. NUCs have
been reported to be associated with lower rates of HBsAg
loss compared to peg-IFN. HBsAg loss has been reported to
occur in 0–2% of HBeAg-positive patients and in <1% of
HBeAg-negative patients at the end of year 1 increasing to
2–8% among HBeAg-positive patients and to 0–5% in
HBeAg-negative patients after 3–5 years of continuous
treatment [10–20,39] (Table 2).
Cohort studies have demonstrated that patients with
chronic HBV infection who lost HBsAg spontaneously have a
reduced risk of cirrhosis, HCC, and liver-related mortality
compared with patients who remained HBsAg positive. In a
prospective cohort study of 218 patients who were followed
up for a mean of 63 months after spontaneous HBsAg
clearance, of the 146 patients who had HBV monoinfection
and who did not have evidence of cirrhosis at the time of
HBsAg loss, none developed cirrhosis or HCC during follow-
up compared to an incidence of cirrhosis of 3.4% and an
incidence of HCC of 0.7% in those who remained HBsAg
positive [58]. Another study of 298 patients found that
patients with HBsAg loss before age 50 years was associated
with a lower risk of HCC [59].
These data indicate that HBsAg loss is a valid surrogate for
clinical outcome and a desired goal during antiviral treat-
ment; however, except for HBV genotype A HBeAg-positive
patients receiving peg-IFN therapy, the low rate of treat-
ment-related HBsAg loss makes HBsAg loss an unrealistic
endpoint in HBV treatment.
CONCLUSIONS
The goal of HBV treatment is to prevent the development of
cirrhosis, HCC, and liver failure. Because clinical outcomes
take decades to evolve, intermediate endpoints have to be
used as surrogates to evaluate the benefits of treatment and
to determine when treatment can be stopped. Data from
clinical trials as well as cohort studies showed that ALT
normalization and HBV DNA suppression are associated
with improved clinical outcomes and are valid surrogates for
assessing the benefits of treatment, but the durability of these
responses is low, and these endpoints cannot be used as
indicators to stop treatment (Table 3). For HBeAg-positive
patients, HBeAg seroconversion is a valid clinical endpoint
and can be used as an indicator for stopping NUC treatment
provided that serum HBV DNA was undetectable and con-
solidation therapy was completed. For HBeAg-negative
patients, HBsAg loss would be an ideal endpoint but the low
rate at which this occurs makes it an unrealistic goal and
other endpoints or predictors of sustained response after NUC
treatment must be sought.
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